2 results
Approved WMORecruiting
To assess the feasibility and efficacy of 90Y-ibritumomab tiuxetan consolidation treatment after R-PECC chemotherapy as second or third line treatment in patients with refractory or relapsed aggressive B-cell NHL, after or not eligible for…
Approved WMORecruiting
Primary objective: Is there a difference in the change in perfused vessel density between obese and lean subjects after cardiac surgery with cardiopulmonary bypass?Secondary Objectives * Is there a difference in baseline perfused vessel density…